Asset Details
Do you wish to reserve the book?
Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
Do you wish to request the book?
Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
2018
Overview
The Southern African HIV Clinicians Society would like to update all HIV-treating clinicians with regard to the use of dolutegravir in women of childbearing potential (WOCP). In preliminary data from the Tsepamo study in Botswana, it was found that 0.94% (95% confidence interval [CI]: 0.37 – 2.4) of babies (4/426) born to women who were taking dolutegravir periconception had neural tube defects (NTDs), compared with 0.1% of babies (14/11 173) of women taking other antiretroviral drugs (ARVs) in the periconception period.1 No NTDs were observed in pregnancies where dolutegravir was initiated later in pregnancy. Further data from the Tsepamo study were presented at AIDS 2018: the updated number of NTDs with periconception dolutegravir exposure in the Tsepamo cohort is 4/596, 0.67% (95% CI: 0.26 to 1.7). The next formal analysis will occur after 31 March 2019 and will include women exposed to dolutegravir from conception before the recent change in guidance. Tsepamo plans to expand the number of study sites, increasing the coverage from 45% to 72% of births in Botswana with a projected denominator of over 1200 by March 2019.
Publisher
AOSIS,African Online Scientific Information Systems (Pty) Ltd t/a AOSIS,AOSIS (Pty) Ltd
